Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with the private U.S. company ZyStor Therapeutics, Inc. This agreement allows ZyStor to evaluate the PER.C6® cell line for use in the manufacturing of a specific therapeutic protein. Financial details were not disclosed.
